Physician profile
Mark L Cerefice
NPI 1417165416
$25,291.91
in general payments reported to CMS, 2019-2025
40 companies · $4,201 in 2025
The $4,201 reported for 2025 was more than what 90% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,341 · 2020: $1,477 · 2021: $2,481 · 2022: $3,408 · 2023: $7,190 · 2024: $4,194 · 2025: $4,201.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Consulting Fee: $2,943 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $20.00 · Grant: $20.00 · Education: $7.75.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,594.07 |
| Consulting Fee | $2,942.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $20.00 |
| Grant | $20.00 |
| Education | $7.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $6,322.25 | 2019-2025 | Stelara, Tremfya, Simponi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $3,858.10 | 2019-2025 | Xifaxan, Plenvu, Trulance |
| Abbvie INC. | $3,276.51 | 2019-2025 | Skyrizi, Linzess, Rinvoq |
| Gilead Sciences, INC. | $1,572.88 | 2019-2025 | Livdelzi |
| Genzyme Corporation | $1,000.94 | 2021-2025 | |
| Madrigal Pharmaceuticals | $926.72 | 2024-2025 | Rezdiffra, Resmetirom |
| Pfizer INC. | $909.54 | 2019-2025 | |
| Celgene Corporation | $815.68 | 2021-2024 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $766.44 | 2019-2025 | Entyvio, Gattex |
| Ardelyx, INC. | $631.09 | 2022-2025 | Ibsrela |
| Daiichi Sankyo INC. | $587.73 | 2019-2024 | Injectafer |
| Redhill Biopharma INC. | $583.37 | 2020-2023 | Talicia, Aemcolo, Movantik |
| Aimmune Therapeutics, INC. | $515.48 | 2024-2025 | Zenpep |
| Lilly USA, LLC | $478.18 | 2023-2025 | Omvoh, Zepbound |
| Nestle Healthcare Nutrition INC. | $448.36 | 2021-2023 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Cerefice listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.